Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab for Recalcitrant Wet AMD (RESCUE)
NCT01972763Phase 2Completed
- Sponsor
- Northern California Retina Vitreous Associates
- Start
- Oct 2013
- Primary completion
- Jul 2018
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ranibizumab in exudative macular degeneration, sponsored by Northern California Retina Vitreous Associates. Started Oct 2013; status: completed.
02
Drugs
ranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT01972763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01972763.